BioDelivery Sciences International, Inc. (BDSI): Price and Financial Metrics
BDSI Price/Volume Stats
| Current price | $5.59 | 52-week high | $5.62 |
| Prev. close | $5.59 | 52-week low | $2.50 |
| Day low | $5.59 | Volume | 2,107,400 |
| Day high | $5.60 | Avg. volume | 3,340,554 |
| 50-day MA | $4.56 | Dividend yield | N/A |
| 200-day MA | $3.81 | Market Cap | 577.05M |
BDSI Stock Price Chart Interactive Chart >
BioDelivery Sciences International, Inc. (BDSI) Company Bio
BioDelivery Sciences International, Inc. engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company was founded in 1997 and is based in Raleigh, North Carolina.
Latest BDSI News From Around the Web
Below are the latest news stories about Biodelivery Sciences International Inc that investors may wish to consider to help them evaluate BDSI as an investment opportunity.
BioDelivery Sciences launches migraine therapy in U.S.BioDelivery Sciences International (BDSI), a specialty pharmaceutical company focused on chronic conditions, announced the U.S. launch of its oral migraine therapy Elyxyb. Also known as celecoxib oral solution, Elyxyb is the first and only oral solution approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute... |
BioDelivery Sciences International (BDSI) Just Flashed Golden Cross Signal: Do You Buy?Good things could be on the horizon when a stock experiences a golden cross event. How should investors react? |
BioDelivery Sciences International Announces ELYXYB™ is Now Available in the U.S. for the Acute Treatment of MigraineThe First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults Expands BDSI Portfolio and Establishes Growth Platform in Neurology RALEIGH, N.C., Feb. 24, 2022 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced the U.S. commercial launch and availability of ELYXYBTM (celecoxib |
What to Expect From Precision BioSciences (DTIL) Q4 EarningsOn Precision BioSciences' (DTIL) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline. |
Biotech Stock Roundup: BDSI Surges on Merger Deal, SGEN Down on Outlook & MoreMerger updates from BioDelivery (BDSI) and Seagen (SGEN) earnings results are among a few key highlights from the biotech sector during the past week. |
BDSI Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | 63.45% |
| 5-year | 20.22% |
| YTD | N/A |
| 2023 | N/A |
| 2022 | 0.00% |
| 2021 | -26.19% |
| 2020 | -33.54% |
| 2019 | 70.81% |
Continue Researching BDSI
Want to do more research on Biodelivery Sciences International Inc's stock and its price? Try the links below:Biodelivery Sciences International Inc (BDSI) Stock Price | Nasdaq
Biodelivery Sciences International Inc (BDSI) Stock Quote, History and News - Yahoo Finance
Biodelivery Sciences International Inc (BDSI) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...